DE69828330D1 - Aktiviertes Protein C Formulierungen - Google Patents

Aktiviertes Protein C Formulierungen

Info

Publication number
DE69828330D1
DE69828330D1 DE69828330T DE69828330T DE69828330D1 DE 69828330 D1 DE69828330 D1 DE 69828330D1 DE 69828330 T DE69828330 T DE 69828330T DE 69828330 T DE69828330 T DE 69828330T DE 69828330 D1 DE69828330 D1 DE 69828330D1
Authority
DE
Germany
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828330T
Other languages
English (en)
Other versions
DE69828330T2 (de
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69828330D1 publication Critical patent/DE69828330D1/de
Publication of DE69828330T2 publication Critical patent/DE69828330T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
DE69828330T 1997-04-28 1998-04-28 Aktiviertes Protein C Formulierungen Expired - Lifetime DE69828330T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
US45255P 1997-04-28

Publications (2)

Publication Number Publication Date
DE69828330D1 true DE69828330D1 (de) 2005-02-03
DE69828330T2 DE69828330T2 (de) 2005-10-13

Family

ID=21936854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828330T Expired - Lifetime DE69828330T2 (de) 1997-04-28 1998-04-28 Aktiviertes Protein C Formulierungen

Country Status (35)

Country Link
US (4) US6159468A (de)
EP (2) EP0875252B1 (de)
JP (2) JP4383546B2 (de)
KR (2) KR100564189B1 (de)
CN (2) CN1227025C (de)
AR (2) AR015598A1 (de)
AT (1) ATE285788T1 (de)
AU (2) AU740753C (de)
BR (2) BR9809292A (de)
CA (2) CA2287267C (de)
CO (2) CO4940438A1 (de)
CZ (1) CZ298429B6 (de)
DE (1) DE69828330T2 (de)
DK (1) DK0875252T3 (de)
EA (2) EA004881B1 (de)
EG (1) EG23685A (de)
ES (1) ES2234072T3 (de)
HK (1) HK1016472A1 (de)
HU (2) HUP0003401A3 (de)
ID (2) ID23172A (de)
IL (2) IL132502A0 (de)
IN (2) IN187157B (de)
MY (2) MY120984A (de)
NO (2) NO995134L (de)
NZ (2) NZ337828A (de)
PE (2) PE86299A1 (de)
PL (2) PL195090B1 (de)
PT (1) PT875252E (de)
SI (1) SI0875252T1 (de)
SV (2) SV1998000050A (de)
TR (2) TR199902529T2 (de)
TW (2) TW585871B (de)
UA (2) UA73071C2 (de)
WO (2) WO1998048818A1 (de)
ZA (2) ZA983496B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337828A (en) 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ATE320263T1 (de) * 1998-11-13 2006-04-15 Lilly Co Eli Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
BR9915460A (pt) * 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
DE69905489T2 (de) * 1998-11-23 2003-09-11 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
IL142249A0 (en) * 1998-12-10 2002-03-10 Lilly Co Eli Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
EP1998266A3 (de) 2001-02-19 2009-02-11 Merck Patent GmbH Verfahren zur Identifizierung von T-Zell-Epitopen und Verfahren zur Herstellung von Molekülen mit verminderter Immunogenität
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
EP1417055A4 (de) * 2001-07-19 2007-09-26 Dmi Biosciences Inc Verwendung von kupferchelatoren zur verhinderung der inaktivierung von protein c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US6838432B2 (en) 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
JP2005528351A (ja) * 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
NZ539811A (en) * 2002-10-29 2008-08-29 Alza Corp Solid-state polypeptide particles that facilitate the loading of an implant delivery system with a concentration of stabilised, therapeutic polypeptide sufficiently high to enable delivery of therapeutic doses of the polypeptide over an extended period of time
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007139553A1 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
EP2041338A4 (de) * 2006-06-09 2009-09-30 Univ British Columbia Interferon-gamma-polymorphismen als indikatoren des patientenergebnisses bei schwerkranken patienten
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
EP2834635A4 (de) 2012-04-03 2015-09-02 Smiths Medical Asd Inc Zusammensetzungen mit einem heparinakkumulationsmittel und verfahren dafür
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
ES2676422T3 (es) 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106573040B (zh) 2014-04-16 2021-07-06 Zz生物技术有限责任公司 治疗异常皮肤瘢痕形成
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
PT3463308T (pt) * 2016-06-01 2022-03-11 Servier Ip Uk Ltd Formulações de óxido de polialquileno asparaginase e métodos de fabrico e utilização do mesmo
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
NZ337828A (en) * 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
IL132325A0 (en) 2001-03-19
HK1016472A1 (en) 1999-11-05
PL195090B1 (pl) 2007-08-31
EP0875252A2 (de) 1998-11-04
ZA983496B (en) 1999-10-25
PL336420A1 (en) 2000-06-19
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
UA73071C2 (en) 2005-06-15
US6395270B1 (en) 2002-05-28
CZ381099A3 (cs) 2000-03-15
CN1227025C (zh) 2005-11-16
DK0875252T3 (da) 2005-04-25
PE86299A1 (es) 1999-09-17
HUP0003401A2 (hu) 2001-02-28
KR100564189B1 (ko) 2006-03-27
NO995198L (no) 1999-10-25
CA2288143C (en) 2012-08-21
CA2287267C (en) 2006-08-15
JP4383546B2 (ja) 2009-12-16
PE84799A1 (es) 1999-09-16
BR9809304A (pt) 2000-10-17
AU7161898A (en) 1998-11-24
EG23685A (en) 2007-05-09
IN187157B (de) 2002-02-16
CO4950523A1 (es) 2000-09-01
NO995134D0 (no) 1999-10-21
EA004881B1 (ru) 2004-08-26
AU740753C (en) 2002-10-10
WO1998048818A1 (en) 1998-11-05
CA2287267A1 (en) 1998-11-05
EP0875252A3 (de) 2000-07-26
DE69828330T2 (de) 2005-10-13
EA199900979A1 (ru) 2000-06-26
AR015598A1 (es) 2001-05-16
KR20010020325A (ko) 2001-03-15
PT875252E (pt) 2005-03-31
CN1261280A (zh) 2000-07-26
EA002149B1 (ru) 2001-12-24
TWI242443B (en) 2005-11-01
HU224826B1 (en) 2006-02-28
EP0875252B1 (de) 2004-12-29
EA199900980A1 (ru) 2000-04-24
IL132502A0 (en) 2001-03-19
WO1998048822A1 (en) 1998-11-05
CZ298429B6 (cs) 2007-10-03
KR20010020242A (ko) 2001-03-15
KR100450856B1 (ko) 2004-10-02
IL132325A (en) 2005-07-25
AU743531B2 (en) 2002-01-31
HUP0100284A3 (en) 2003-08-28
EP0875563A3 (de) 2000-08-02
US6159468A (en) 2000-12-12
SV1998000051A (es) 1998-12-11
AU7258998A (en) 1998-11-24
CO4940438A1 (es) 2000-07-24
NO995134L (no) 1999-12-21
ATE285788T1 (de) 2005-01-15
NZ337828A (en) 2001-06-29
TR199902529T2 (xx) 2000-02-21
NO995198D0 (no) 1999-10-25
HUP0003401A3 (en) 2003-01-28
ZA983497B (en) 1999-10-25
MY120984A (en) 2005-12-30
AR012010A1 (es) 2000-09-13
TR199902631T2 (xx) 2000-01-21
PL195642B1 (pl) 2007-10-31
JP2001524111A (ja) 2001-11-27
MY118591A (en) 2004-12-31
SI0875252T1 (en) 2005-06-30
HUP0100284A2 (hu) 2001-06-28
IN183798B (de) 2000-04-15
PL336889A1 (en) 2000-07-17
US6436397B1 (en) 2002-08-20
ID23172A (id) 2000-03-23
SV1998000050A (es) 1999-01-13
BR9809304B1 (pt) 2011-02-08
BR9809292A (pt) 2000-07-04
TW585871B (en) 2004-05-01
JP2001527543A (ja) 2001-12-25
AU740753B2 (en) 2001-11-15
CA2288143A1 (en) 1998-11-05
CN1254284A (zh) 2000-05-24
EP0875563A2 (de) 1998-11-04
NZ500346A (en) 2001-08-31
CN1235638C (zh) 2006-01-11
ES2234072T3 (es) 2005-06-16
US6162629A (en) 2000-12-19
ID22933A (id) 1999-12-16

Similar Documents

Publication Publication Date Title
ATE285788T1 (de) Aktiviertes protein c formulierungen
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
NO986208D0 (no) Vandige peptidformuleringer
CY2006006I2 (el) Πρωτεϊνικα σκευασματα
MA24473A1 (fr) Formulations
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
NO20001494D0 (no) Overligger
DE69801399T2 (de) Urladen
DE69705017T2 (de) Medikamente bindendes Protein
DE69837507D1 (de) Humanes Hedgehog-Protein
DK0862850T3 (da) Mejetærsker
ATE295417T1 (de) Angiostatin-bindendes protein
ID23663A (id) Persiapan kaprolaktam
DE29808202U1 (de) Fußstütze
DE29704970U1 (de) Fußstütze
DE29719589U1 (de) Vereinzelner
KR980000493U (ko) 의자
DE29702452U1 (de) Fußstütze
NO970852D0 (no) Fotböyle
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
ITMI972543A0 (it) Proteina p27bbp
KR980000498U (ko) 의자
NO973887L (no) Arbeidsstol
KR970050786U (ko) 의자

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN